English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

CD24  is a glycosyl-phosphatidyl-inositol linked glycoprotein expressed in a broad range of cell types including cancer cells. Although it is overexpressed in nearly 70% of human cancers, copy number variation of the  CD24  locus has not been reported for any cancer. Here, we analyzed the genomics, transcriptomics, and clinical data of 1082 breast cancer (BRCA) samples and other cancer samples from the clinically annotated genomic database, The Cancer Genome Atlas (TCGA). The GISTIC2 method was applied to stratify the  CD24  copy number, and Cox regression was performed to compare hazard ratio (HR) of  CD24  overexpression, amplification and other traditional prognosis features for overall survival (OS). Our data demonstrated that  CD24  amplification strongly correlated with its mRNA overexpression as well as  TP53  mutant, cancer proliferation and metastasis features. In particular,  CD24  amplification was enriched in basal-like subtype samples and associated with poor clinical outcome. Surprisingly, based on the univariate Cox regression analysis,  CD24  overexpression ( HR  = 1.62,  P  = 0.010) and copy number amplification ( HR  = 1.79,  P  = 0.022) was more relevant to OS than  TP53  mutant, mutation counts, diagnosis age, and BRCA subtypes. And based on multivariate survival analysis,  CD24  amplification remained the most significant and independent predictor for worse OS ( HR  = 1.88,  P  = 0.015).

Amplification of the CD24 Gene Is an Independent Predictor for Poor Prognosis of Breast Cancer